# Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants

> **NCT00807235** · PHASE2 · TERMINATED · sponsor: **Windtree Therapeutics** · enrollment: 17 (actual)

## Conditions studied

- Respiratory Distress Syndrome

## Interventions

- **DRUG:** Aerosolized lucinactant
- **DRUG:** Aerosolized lucinactant

## Key facts

- **NCT ID:** NCT00807235
- **Lead sponsor:** Windtree Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2005-08
- **Final completion:** 2005-09
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2012-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807235, "Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00807235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*